Pharma BD Deal Intelligence

Roche Holding AG / Anadys Pharmaceuticals, Inc.

2010 · Acquisition/Merger · $230M · Complete

Roche to acquire Anadys at $3.70/share cash, ~$230M (256% premium). Strengthened Roche HCV portfolio with setrobuvir Phase 2 candidate.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.